Evaluation of Prostate-Specific Membrane Antigen (PSMA) Immunohistochemical Expression in Early-Stage Breast Cancer Subtypes
Open Access
- 13 June 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (12) , 6519
Abstract
Breast cancer, known for its diverse subtypes, ranks as one of the leading causes of cancer-related deaths. Prostate-specific membrane antigen (PSMA), primarily associated with prostate cancer, has also been identified in breast cancer, though its role remains unclear. This study aimed to evaluate PSMA expression across different subtypes of early-stage breast cancer and investigate its correlation with clinicopathological factors. This retrospective study included 98 breast cancer cases. PSMA expression was examined in both tumor cells and tumor-associated blood vessels. The analysis revealed PSMA expression in tumor-associated blood vessels in 88 cases and in tumor cells in 75 cases. Ki67 expression correlated positively with PSMA expression in blood vessels (p < 0.0001, RSpearman 0.42) and tumor cells (p = 0.010, RSpearman 0.26). The estrogen and progesterone receptor expression correlated negatively with PSMA levels in blood vessels (p = 0.0053, R Spearman −0.26 and p = 0.00026, R Spearman −0.347, respectively). Human epidermal growth factor receptor 2 (HER2) status did not significantly impact PSMA expression. We did not detect any statistically significant differences between breast cancer subtypes. These findings provide evidence for a heterogenous PSMA expression in breast cancer tissue and suggest its correlation with tumor aggressiveness. Despite the limited sample size, the study provides valuable insights into the potential of PSMA as a prognostic, diagnostic, and therapeutic target in the management of breast cancer.Keywords
Funding Information
- Ministry of Science and Higher Education of the Republic of Poland (DI2019 013549)
This publication has 29 references indexed in Scilit:
- The real‐world outcomes of Lutetium‐177 PSMA‐617 radioligand therapy in metastatic castration‐resistant prostate cancer: Turkish Oncology Group multicenter studyInternational Journal of Cancer, 2023
- Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imagingScientific Reports, 2022
- Expression of Prostate Specific Membrane Antigen (PSMA) in Breast CancerGeburtshilfe und Frauenheilkunde, 2022
- E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapyBreast Cancer Research and Treatment, 2018
- Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastasesClinical & Experimental Metastasis, 2017
- 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptideAngiogenesis, 2016
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003